American Journal of Cardiology
Volume 102, Issue 4 , Pages 424-428 , 15 August 2008

Comparison of Serum Lipid Values in Subjects With and Without the Metabolic Syndrome

  • Alberto Cordero, PhD

      Affiliations

    • Department of Cardiology, Hospital Universitario de San Juan, Alicante, Spain
    • Corresponding Author InformationCorresponding author: Tel: 34-965-938-730; fax: 34-965-938-652.
    • ,
  • Martín Laclaustra, PhD

      Affiliations

    • Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
    • ,
  • Montserrat León, PhD

      Affiliations

    • Cardiovascular Research Unit, Hospital Clínico Universitario, Zaragoza, Spain
    • ,
  • José A. Casasnovas, PhD

      Affiliations

    • Cardiovascular Research Unit, Hospital Clínico Universitario, Zaragoza, Spain
    • ,
  • Alberto Grima, PhD

      Affiliations

    • Department of Preventive Cardiology, Asepeyo, Valencia, Spain
    • ,
  • Emilio Luengo, PhD

      Affiliations

    • Cardiovascular Research Unit, Hospital Clínico Universitario, Zaragoza, Spain
    • ,
  • Beatriz Ordoñez, PhD

      Affiliations

    • Cardiovascular Research Unit, Hospital Clínico Universitario, Zaragoza, Spain
    • ,
  • Clara Bergua, PhD

      Affiliations

    • Cardiovascular Research Unit, Hospital Clínico Universitario, Zaragoza, Spain
    • ,
  • María Bes

      Affiliations

    • Cardiovascular Research Unit, Hospital Clínico Universitario, Zaragoza, Spain
    • ,
  • Isaac Pascual, MD

      Affiliations

    • Cardiovascular Research Unit, Hospital Clínico Universitario, Zaragoza, Spain
    • ,
  • Eduardo Alegría, PhD

      Affiliations

    • Department of Cardiology, Clinica Universitaria de Navarra, Pamplona, Spain.
    • ,
  • MESYAS Registry Investigators

Received 4 February 2008 ,Revised 24 March 2008 ,Accepted 24 March 2008.

References 

  1. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414–419
  2. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107:391–397
  3. Levantesi G, Macchia A, Marfisi R, Franzosi MG, Maggioni AP, Nicolosi GL, et al. Metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol. 2005;46:277–283
  4. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49:403–414
  5. Golden SH, Folsom AR, Coresh J, Sharrett AR, Szklo M, Brancati F. Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study. Diabetes. 2002;51:3069–3076
  6. Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006;368:919–928
  7. Cordero A, Laclaustra M, Leon M, Grima A, Casasnovas JA, Luengo E, et al. Prehypertension is associated with insulin resistance state and not with an initial renal function impairment (A Metabolic Syndrome in Active Subjects in Spain (MESYAS) registry substudy). Am J Hypertens. 2006;19:189–196
  8. Cordero A, Laclaustra M, Leon M, Casasnovas JA, Grima A, Najar M, et al. Cardiovascular risk factors and metabolic syndrome associated with subclinical renal failure. Med Clin (Barc). 2005;125:653–658
  9. Alegria E, Cordero A, Laclaustra M, Grima A, Leon M, Casasnovas JA, et al. Prevalence of metabolic syndrome in the Spanish working population: MESYAS registry. Rev Esp Cardiol. 2005;58:797–806
  10. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  11. Grundy SM, Howard B, Smith S, Eckel R, Redberg R, Bonow RO. Prevention conference VI: diabetes and cardiovascular disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation. 2002;105:2231–2239
  12. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007;115:928–935
  13. Reaven GM. Banting lecture 1988 (Role of insulin resistance in human disease). Diabetes. 1988;37:1595–1607
  14. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415–1428
  15. Criqui MH, Heiss G, Cohn R, Cowan LD, Suchindran CM, Bangdiwala S, et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med. 1993;328:1220–1225
  16. Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation. 1997;96:2520–2525
  17. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Low triglycerides-high high-density lipoprotein cholesterol and risk of ischemic heart disease. Arch Intern Med. 2001;161:361–366
  18. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–1310
  19. deGoma EM, Leeper NJ, Heidenreich PA. Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J Am Coll Cardiol. 2008;51:49–55
  20. Laclaustra M, Corella D, Ordovas JM. Metabolic syndrome pathophysiology: the role of adipose tissue. Nutr Metab Cardiovasc Dis. 2007;17:125–139
  21. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men (Prospective results from the Quebec Cardiovascular Study). Circulation. 1997;95:69–75
  22. Hayashi Y, Okumura K, Matsui H, Imamura A, Miura M, Takahashi R, et al. Impact of low-density lipoprotein particle size on carotid intima-media thickness in patients with type 2 diabetes mellitus. Metabolism. 2007;56:608–613
  23. Hulthe J, Bokemark L, Wikstrand J, Fagerberg B. The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study. Arterioscler Thromb Vasc Biol. 2000;20:2140–2147
  24. Reilly MP, Wolfe ML, Rhodes T, Girman C, Mehta N, Rader DJ. Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation. 2004;110:803–809
  25. Sumner AE, Finley KB, Genovese DJ, Criqui MH, Boston RC. Fasting triglyceride and the triglyceride–HDL cholesterol ratio are not markers of insulin resistance in African Americans. Arch Intern Med. 2005;165:1395–1400

 Dr. Laclaustra was supported by the Research Program of Instituto de Salud “Carlos III,” Formación Sanitaria Especializada, Madrid, Spain.

PII: S0002-9149(08)00656-5

doi: 10.1016/j.amjcard.2008.03.079

American Journal of Cardiology
Volume 102, Issue 4 , Pages 424-428 , 15 August 2008

Article Tools

* Image Usage & Resolution